Scinai Immunotherapeutics Ltd
SCNI0.832USD
-0.017-2.01%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.26MMarktkapitalisierung
0.07KGV TTM
mehr Informationen über Scinai Immunotherapeutics Ltd Unternehmen
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltd Informationen
BörsenkürzelSCNI
Name des UnternehmensScinai Immunotherapeutics Ltd
IPO-datumJun 07, 2007
CEOReichman (Amir)
Anzahl der mitarbeiter31
WertpapierartDepository Receipt
GeschäftsjahresendeJun 07
AddresseJerusalem Biopark, 2Nd Floor
StadtJERUSALEM
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl00000
Telefon97289302529
Websitehttps://www.scinai.com/
BörsenkürzelSCNI
IPO-datumJun 07, 2007
CEOReichman (Amir)
Führungskräfte von Scinai Immunotherapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+5677.00%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
+1355.00%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
+1272.00%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
+276.00%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-18.00%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+17.00%
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+17.00%
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
--
--
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+5677.00%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
+1355.00%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
+1272.00%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
+276.00%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-18.00%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+17.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
Andere
87.54%
Aktionäre
Aktionäre
Anteil
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
Andere
87.54%
Aktionärstypen
Aktionäre
Anteil
Corporation
8.10%
Hedge Fund
2.54%
Individual Investor
2.20%
Investment Advisor
1.41%
Investment Advisor/Hedge Fund
0.84%
Andere
84.91%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
22
166.27K
4.79%
+79.52K
2025Q3
20
247.18K
7.75%
+209.10K
2025Q2
33
391.87K
45.94%
+279.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RK Stone Miami, LLC
200.00K
5.77%
+200.00K
--
Sep 29, 2025
LCK JNK 1 LLC
80.76K
2.33%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
64.20K
1.85%
+1.80K
+2.88%
Sep 29, 2025
Armistice Capital LLC
44.80K
1.29%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
1.23%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
0.84%
+29.05K
--
Dec 31, 2024
Citadel Advisors LLC
28.63K
0.83%
+17.03K
+146.83%
Sep 30, 2025
Two Sigma Investments, LP
14.70K
0.42%
+14.70K
--
Sep 30, 2025
Reichman (Amir)
8.08K
0.23%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
3.55K
0.1%
+70.00
+2.01%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
